市场监管总局：12起典型案件罚款超24亿，有效遏制药品领域垄断行为

Core Viewpoint - The State Administration for Market Regulation (SAMR) has imposed fines exceeding 2.4 billion yuan on 12 typical cases of monopolistic behavior in the pharmaceutical sector, effectively curbing monopolistic practices in the industry [1][2]. Group 1: Enforcement Actions - SAMR has prioritized combating monopolistic behavior in the pharmaceutical sector, focusing on key drugs that affect public health, such as essential and emergency medications [1]. - A total of 12 cases of monopolistic agreements and abuse of market dominance have been investigated over the past three years, resulting in fines totaling over 2.4 billion yuan [1][2]. - The enforcement approach includes rapid investigation and resolution, with over 850 personnel involved in investigating more than 40 upstream and downstream companies across 10 provinces [1]. Group 2: Penalties and Deterrence - The average penalty for the 12 cases was 5% of the previous year's sales, with an average fine exceeding 200 million yuan [2]. - In specific cases, such as the monopolistic behavior involving methanesulfonic acid injection, penalties reached the maximum of 10% of the previous year's sales, with fines imposed on both companies and responsible individuals [2]. - The enforcement strategy includes a threefold punishment system targeting companies, organizers, and responsible individuals to enhance deterrent effects [2]. Group 3: Regulatory Framework and Collaboration - SAMR has established guidelines for antitrust actions in the pharmaceutical sector, clarifying the recognition of monopolistic behaviors such as price collusion and abuse of market dominance [2]. - There is a focus on collaborative efforts with health, public security, medical insurance, and drug supervision departments to enhance enforcement effectiveness and information sharing [2]. - The enforcement actions have led to significant price reductions for certain medications, with prices dropping by 95.8% and 58.6% for specific drugs [2]. Group 4: Future Commitment - SAMR will continue to prioritize the pharmaceutical sector in its antitrust enforcement efforts, maintaining a strict and rapid response to monopolistic practices [3].